792 related articles for article (PubMed ID: 21956718)
1. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
Ito D; Suzuki N
Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
[TBL] [Abstract][Full Text] [Related]
2. [Conjoint pathological cascades mediated by RNA-binding proteins, TDP-43, FUS and ataxin-2].
Ito D
Rinsho Shinkeigaku; 2012; 52(11):1221-3. PubMed ID: 23196570
[TBL] [Abstract][Full Text] [Related]
3. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS).
Nihei Y; Ito D; Suzuki N
J Biol Chem; 2012 Nov; 287(49):41310-23. PubMed ID: 23048034
[TBL] [Abstract][Full Text] [Related]
4. Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma.
Bentmann E; Haass C; Dormann D
FEBS J; 2013 Sep; 280(18):4348-70. PubMed ID: 23587065
[TBL] [Abstract][Full Text] [Related]
5. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
6. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
Baloh RH
Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
[TBL] [Abstract][Full Text] [Related]
7. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
[TBL] [Abstract][Full Text] [Related]
8. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.
Sun Z; Diaz Z; Fang X; Hart MP; Chesi A; Shorter J; Gitler AD
PLoS Biol; 2011 Apr; 9(4):e1000614. PubMed ID: 21541367
[TBL] [Abstract][Full Text] [Related]
10. "STRESSED OUT": The role of FUS and TDP-43 in amyotrophic lateral sclerosis.
Aksoy YA; Deng W; Stoddart J; Chung R; Guillemin G; Cole NJ; Neely GG; Hesselson D
Int J Biochem Cell Biol; 2020 Sep; 126():105821. PubMed ID: 32758633
[TBL] [Abstract][Full Text] [Related]
11. TDP-43 and FUS: a nuclear affair.
Dormann D; Haass C
Trends Neurosci; 2011 Jul; 34(7):339-48. PubMed ID: 21700347
[TBL] [Abstract][Full Text] [Related]
12. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
[TBL] [Abstract][Full Text] [Related]
13. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
14. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43.
Lanson NA; Maltare A; King H; Smith R; Kim JH; Taylor JP; Lloyd TE; Pandey UB
Hum Mol Genet; 2011 Jul; 20(13):2510-23. PubMed ID: 21487023
[TBL] [Abstract][Full Text] [Related]
15. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
[TBL] [Abstract][Full Text] [Related]
16. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
[TBL] [Abstract][Full Text] [Related]
17. TDP-43 and FUS en route from the nucleus to the cytoplasm.
Ederle H; Dormann D
FEBS Lett; 2017 Jun; 591(11):1489-1507. PubMed ID: 28380257
[TBL] [Abstract][Full Text] [Related]
18. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
Ratti A; Buratti E
J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757
[TBL] [Abstract][Full Text] [Related]
19. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.
Deng Q; Holler CJ; Taylor G; Hudson KF; Watkins W; Gearing M; Ito D; Murray ME; Dickson DW; Seyfried NT; Kukar T
J Neurosci; 2014 Jun; 34(23):7802-13. PubMed ID: 24899704
[TBL] [Abstract][Full Text] [Related]
20. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
Neumann M
Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
